Thynk Capital, LLC.

Thynk Capital, founded by Jim Plante, is focused on early-stage Therapeutics, Healthcare, and Technology companies. We tend to invest early in capital-efficient companies, generating momentum with critical resources that further product development, clinical trials, and regulatory approvals. In therapeutics, we typically invest when drug candidates are in the pre-clinical or early clinical phase, but on occasion, we have partnered in drug discovery. Our investment strategy has a strong focus on opportunities that have the potential of becoming an innovative break thru, a modern replacement, or a complement to existing products on the market. We pursue opportunities which present unmet needs in commercially attractive markets, and we produce products which are likely to receive attractive reimbursement and pricing structures, once regulatory approval is achieved. We have a preference for companies targeting widespread diseases that are either unchecked or already being addressed ineffectively by established medical treatment. We’re firm believers that when developing a successful company, the key factor is the quality of the management team. Less experienced management teams with savvy and potential must be open to change if needed to accelerate the company. We are committed to working hands-on with our portfolio companies to accomplish objectives and build value. In most cases, Thynk Capital works closely with the management team and the board members to develop the company.